Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor
Breast Cancer Research and Treatment · 2025
DOI: 10.1007/s10549-024-07578-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Diego Malon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, 700 University Ave, Toronto, ON, M5G 1Z5, Can…. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Fatty Liver, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Hold'em for Life Oncology Fellowships at the University of Toronto’s Temerty Faculty of Medicine..
Abstract (Originalsprache)
PURPOSE: In early-stage breast cancer, steatotic liver disease (SLD) is associated with increased recurrence, cardiovascular events, and non-cancer death. Endocrine therapy (ET) increases the risk of SLD. The impact of cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) on SLD and prognostic association in metastatic breast cancer is unknown. We characterized the presence of SLD, risk factors, and treatment outcomes of SLD in metastatic HR+/HER2- breast cancer receiving CDK4/6i. METHODS: This single institution, retrospective, cohort study included patients with metastatic HR+/HER2- breast cancer receiving first-line ET and CDK4/6i from January 2018 to June 2022. SLD was defined as a Liver Attenuation Index (LAI) > 25 HU on contrast-enhanced CT scans and/or > 10 HU on plain CT scans. Univariable binary-logistic regression was used to assess associations with SLD. Time to treatment failure (TTF) and overall survival (OS) were analyzed using Cox proportional hazards modeling. RESULTS: Among 87 patients with a median age of 58 years and 65.5% postmenopausal, 50 (57.5%) had SLD at anytime (24 at baseline, 26 acquired). SLD at baseline was statistically associated with post-menopausal status. It was quantitatively but not statistically associated with age > 65, diabetes, smoking, and HER2-low. SLD at anytime was statistically significantly associated with longer TTF (median 470 vs 830.5 days, HR = 0.38, p < 0.001). No significant differences in OS or grade 3/4 adverse events were observed between groups. CONCLUSION: This study demonstrated a high prevalence of SLD in this population, with SLD presence correlated with longer TTF. SLD may be an indicator of better outcomes in metastatic HR+/HER2- breast cancer patients treated with CDK4/6i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, 700 University Ave, Toronto, ON, M5G 1Z5, Canada. diego.malongimenez@uhn.ca.
- University of Toronto, Toronto, ON, Canada. diego.malongimenez@uhn.ca.
- Department of Oncology, Queen's University, Kingston, ON, Canada.
- Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada.
- R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, ON, Canada.
- Joint Department of Medical Imaging (JDMI), University Health Network, Toronto, ON, Canada.
Förderung
- Hold'em for Life Oncology Fellowships at the University of Toronto’s Temerty Faculty of Medicine.
Zitieren
APA
Malon, D., Molto, C., Prasla, S., Cuthbert, D., Pathak, N., Berner-Wygoda, Y., Di Lorio, M., Li, M., Savill, J., Mittal, A., Amir, E., Jhaveri, K., & Nadler, M. B. (2025). Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07578-2
Vancouver
Malon D, Molto C, Prasla S, Cuthbert D, Pathak N, Berner-Wygoda Y, et al. Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-024-07578-2
BibTeX
@article{Malon2025,
author = {Malon, Diego and Molto, Consolacion and Prasla, Shopnil and Cuthbert, Danielle and Pathak, Neha and Berner-Wygoda, Yael and Di Lorio, Massimo and Li, Meredith and Savill, Jacqueline and Mittal, Abhenil and Amir, Eitan and Jhaveri, Kartik and Nadler, Michelle B},
title = {Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor},
journal = {Breast Cancer Research and Treatment},
year = {2025},
doi = {10.1007/s10549-024-07578-2}
}
EUVIMED